Highlights
- 1Nature cell biology · 2023
- 2
- 3
Publications
26 publications
Funding
5 grants
Active
3 grants- KPR01DK125817-01A1Investigating a master regulator of large intestine stem cellsNational Institute of Diabetes and Digestive and Kidney Diseases · 2021–2026
- Co-IR01DK133701-01Engineering islet-like organoids from gastric stem cells for T1D cell replacement therapyNational Institute of Diabetes and Digestive and Kidney Diseases · 2022–2026
- Co-IR01DK133332-01Derivation of pancreatic islet-like organoids from human gastric stem cellsNational Institute of Diabetes and Digestive and Kidney Diseases · 2022–2026
Completed grants (2)
- Co-IDFI 226165-01Developing a novel cell therapy to treat Type 1 diabetesDaedalus Fund for Innovation (Weill Cornell) · 2022–2025BioPharma Alliance
- KPUC4DK116280-02Generating novel sources of functional human insulin-secreting cells for T1D modelingNational Institute of Diabetes and Digestive and Kidney Diseases · 2019–2022
Available technologies
2 technologiesView full WCM portfolio ↗
- CRISPR-Mediated SATB2 Inhibition for the Treatment of Short Bowel Syndrome9894Application filedPoC DataPMID 38678016PMID 34582804
- Generation of Glucose-Responsive Stomach Cells for the Treatment of DiabetesApplication filedPoC DataPMID 37163124
News mentions
3 mentionsView all WCM news ↗
- Reprogramming Gut Cells to Treat Short Bowel SyndromeApril 3, 2025
Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine, according to a new study by Weill Cornell Medicine investigators.
- Scientists Pitch Medical Innovations at 2023 Biomedical Business Plan ChallengeJune 16, 2023
Six teams pitched their innovations at the 2023 Biomedical Business Plan Challenge Final Pitch Day competition for $100,000 in prize money, which can be used to help build their company, with the goal of ushering in the next generation of life science innovation and patient care.
- Scientists Target Human Stomach Cells for Diabetes TherapyMay 23, 2023
Stem cells from the human stomach can be converted into cells that secrete insulin in response to rising blood sugar levels, offering a promising approach to treating diabetes.
External relationships
Professional Services
Johnson & Johnson